ANTIBODY LIBRARIES
The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity.
1 - 41 . (canceled)
42 . A library of synthetic polynucleotides encoding light chain variable regions, wherein the polypeptide sequences of the light chain variable regions are varied at two or three residues between positions 89 to 94, inclusive, of the variable light chain polypeptide sequence.
43 . The library of claim 42 , wherein the library comprises polynucleotides encoding light chain variable regions comprising polypeptide sequences at least about 80%, 90%, or 95% identical to polypeptides produced by translation of two or more of the polynucleotide sequences provided in Tables 5-7.
44 . The library of claim 42 , wherein the light chain variable regions comprise the polypeptides produced by translation of the polynucleotide sequences provided in Tables 5-7.
45 . A method of making synthetic polynucleotides encoding a CDRL3 library, comprising:
(i) obtaining a reference set of light chain sequences, wherein the reference set contains light chain sequences with VL segments originating from the same IGVL germline gene and/or its allelic variants;
(ii) determining which amino acids occur at each of the CDRL3 positions in the reference set that are encoded by the IGVL gene;
(iii) synthesizing light chain variable domain encoding sequences wherein two or three positions between positions 89 and 94, inclusive, contain degenerate codons encoding two or more of the five most frequently occurring amino acid residues at the corresponding positions in the reference set; and
(iv) synthesizing the polynucleotides encoding the CDRL3 library.
46 . A library of polynucleotides made according to the method of claim 45 .
47 . The method of claim 45 , wherein the CDRL3 library contains kappa light chain and/or lambda light chain sequences.
48 . The method of claim 47 , wherein
(i) the kappa CDRL3 sequences comprise FT, LT, IT, RT, WT, YT, [X]T, [X]PT, [X]FT, [X]LT, [X]IT, [X]RT, [X]WT, [X]YT, [X]PFT, [X]PLT, [X]PIT, [X]PRT, [X]PWT and [X]PYT, where [X] corresponds to the amino acid residue found at position 95 (Kabat) in the respective VK germline sequence; and
(ii) the lambda CDRL3 sequences comprise YV, VV, WV, AV or V.
49 . The method of claim 48 , wherein [X] is P or S.